CHGA and posterior cortical atrophy: More in detail, tumors from patients who satisfied at least one of the following clinical criteria (i.e., having undergone clinical progression; died for PCa; having received hormonotherapy; tumor positivity for perineural invasion) together with high levels of Chromogranin A (signal intensity higher than the median value across samples, as assessed by gene expression profiling) were classified as neuroendocrine-like tumors (NE-like, n = 22).